Abstract: A method for determining a pressure profile in a subterranean formation is described. The method includes drilling a wellbore in the subterranean formation; lowering a logging tool into the wellbore to measure resistivity values as a function of depth along the wellbore; identifying a plurality of porous zones from the wellbore based on petrophysical logs; converting the measured resistivity values to an amount of total dissolved solids for each of the plurality of identified porous zones; converting the amount of total dissolved solids to a pore fluid density; calculating a pressure based on a sum of the pore fluid densities derived along a length of the well; and generating a depth-based pressure profile.

Abstract: A process for drilling a well into a subsurface formation includes receiving data representing depth maps for a given subsurface region, each depth map being generated from seismic data acquired in a seismic survey at a subsurface region. The process includes determining, for depth maps of the plurality, respective weight values; generating data representing a combination of the depth maps based on the respective weight values; generating a cumulative distribution function (CDF) for a particular location in the subsurface region based on the data representing a combination of the depth maps; determining, based on the CDF for that particular location, a probability value representing a depth at which a geological layer occurs in the subsurface region at the particular location; and drilling the well into the subsurface formation at the particular location to a target depth based on the probability value.

Abstract: The present disclosure relates to a pharmaceutical combination comprising (a) a histone deacetylase 6 inhibitor and (b) a programmed death ligand 1 (PD-L1) inhibitor, including combined preparations and pharmaceutical compositions thereof; uses of such combination in the treatment or prevention of cancer; and methods of treating or preventing cancer in a subject comprising administering a therapeutically effective amount of such combination.

Abstract: The present disclosure relates to a pharmaceutical combination comprising (a) a histone deacetylase inhibitor and (b) a CD38 inhibitor, FIG. 1A including combined preparations and pharmaceutical compositions thereof; uses of such combination in the treatment or prevention of cancer; and methods of treating or preventing cancer in a subject comprising administering a therapeutically effective amount of such combination.

Abstract: In accordance with one or more embodiments of the present disclosure, a method of subsurface sequestration of CO2 in a geological basin includes identifying one or more subsurface sequestration locations in the geological basin and injecting an aqueous CO2 solution to be sequestered into the geological basin. The one or more subsurface sequestration locations are regions of deeper geological structure, relative to an adjacent shallower geological structure, into which a negatively buoyant fluid injected into the basin will sink. The aqueous CO2 solution comprises a density that is greater than the density of the water naturally present in the geological basin, such that the injected aqueous CO2 solution pools in the one or more subsurface sequestration locations.

Abstract: Systems and methods include a computer-implemented method for displaying well information. Geological boundaries are identified for a group of multiple wells in a region including a reference well. Each well has geological boundaries at depths different from boundaries in the reference well. A framework of the geological boundaries of the reference well multiple wells is treated as a set of datums for shifting pressures relative to the reference well. Geological boundaries of the group of multiple wells are matched, including identifying tops and bases of geological layers for each well. Depth shifts for depths having corresponding pressure data are determined. The depth shifts are redatumed based on differences in depth of the geological layers of each well. A display of a graph is presented in a graphical user interface (GUI). The graph maps pressures of the group of multiple wells at different depths and based on redatuming of each well.

Abstract: Embodiments herein relate to a computer-implemented technique that includes generating, in a first portion of a graphical user interface (GUI), a first graphical element related to reflection seismic data of an area of interest. The technique further includes generating, in a second portion of the GUI, a second graphical element related to well structural data of the area of interest. The technique further includes generating, in a third portion of the GUI, a third graphical element that is based on the reflection seismic data and the well structural data. In embodiments, an alteration of the first graphical element or the second graphical element results in a concurrent alteration of the third graphical element. Other embodiments may be described or claimed.

Abstract: Systems and methods include a method used in drilling wells. A three-dimensional (3D) uncertainty cube is generated for a subsurface geological structure containing a well target for drilling operations of a well. The 3D uncertainty cube defines an uncertainty of a geological position relative to a 3D structural model. The 3D uncertainty cube is dynamically updated in real time while drilling the well, including parameterizing the 3D uncertainty cube for a distance ahead of a drill bit. A probability that the well target will be hit is determined using the 3D uncertainty cube. The drilling operations of the well are dynamically re-planned and re-steered based on the updated 3D uncertainty cube, including updating a direction of the drilling operations of the well using the 3D uncertainty cube and the probability. Drilling and acquiring new information are continued to iteratively continue dynamic updates and continued drilling.

Abstract: The present disclosure relates to a pharmaceutical combination comprising (a) a histone deacetylase inhibitor and (b) a CD38 inhibitor, including combined preparations and pharmaceutical compositions thereof; uses of such combination in the treatment or prevention of cancer; and methods of treating or preventing cancer in a subject comprising administering a therapeutically effective amount of such combination.

Abstract: Systems and methods include a computer-implemented method includes concurrently outputting, by a computing device to a display of the computing device, a graphical time-domain interpretation of seismic data, a graphical velocity model related to the seismic data, and a graphical depth-domain interpretation of the seismic data. The method may further include identifying, by the computing device, a first alteration to one of the time-domain interpretation, the velocity model, and the depth-domain interpretation. The method may further include identifying, by the computing device based on the first alteration, a second alteration to another of the time-domain interpretation, the velocity model, and the depth-domain interpretation. The method may further include updating, by the computing device based on the first alteration and the second alteration, at least two of the graphical time-domain interpretation, the graphical velocity model, and the graphical depth-domain interpretation.

Abstract: The invention relates to histone deacetylase (HDAC) biomarkers in multiple myeloma. Specifically, the biomarkers are drug specific, histone deacetylase (HDAC) or HDAC6 biomarker RNAs for multiple myeloma. The invention also relates to a kit for determining the treatment efficiency of a HDAC6 inhibitor, and a kit for identifying a histone deacetylase 6 (HDAC6) inhibitor. The invention further relates to a method for monitoring treatment efficiency of an HDAC inhibitor in a subject.

Abstract: The invention relates to combinations comprising an HDAC inhibitor and an immunomodulatory drug for the treatment of multiple myeloma in a subject in need thereof. The combinations may, optionally, further comprise an anti-inflammatory agent, such as dexamethasone. Also provided herein are methods for treating multiple myeloma in a subject in need thereof comprising administering to the subject an effective amount of one of the above combinations.

Abstract: The present disclosure relates to a pharmaceutical combination comprising (a) a histone deacetylase inhibitor and (b) a CD38 inhibitor, including combined preparations and pharmaceutical compositions thereof; uses of such combination in the treatment or prevention of cancer; and methods of treating or preventing cancer in a subject comprising administering a therapeutically effective amount of such combination.

Abstract: The present disclosure relates to a pharmaceutical combination comprising (a) a histone deacetylase 6 inhibitor and (b) a programmed death ligand 1 (PD-L1) inhibitor, including combined preparations and pharmaceutical compositions thereof; uses of such combination in the treatment or prevention of cancer; and methods of treating or preventing cancer in a subject comprising administering a therapeutically effective amount of such combination.

Abstract: The invention relates to combinations comprising an HDAC inhibitor and an immunomodulatory drug for the treatment of lymphoma in a subject in need thereof. Also provided herein are methods for treating lymphoma in a subject in need thereof comprising administering to the subject an effective amount of one of the above combinations.

Abstract: Provided herein are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with HDAC activity, particularly diseases or disorders that involve activity of HDAC1, HDAC2, and/or HDAC6. Also provided herein are methods for inhibiting migration of a neuroblastoma cell, inducing maturation of a neuroblastoma cell, and altering cell cycle progression of a neuroblastoma cell comprising administering to the cell a therapeutically effective amount of a HDAC1, HDAC2, and/or HDAC6 selective inhibitor or a pharmaceutically acceptable salt thereof.

Abstract: Provided herein are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with HDAC activity, particularly diseases or disorders that involve activity of HDAC1, HDAC2, and/or HDAC6. Also provided herein are methods for inhibiting migration of a neuroblastoma cell, inducing maturation of a neuroblastoma cell, and altering cell cycle progression of a neuroblastoma cell comprising administering to the cell a therapeutically effective amount of a HDAC1, HDAC2, and/or HDAC6 selective inhibitor or a pharmaceutically acceptable salt thereof.

Abstract: The invention relates to histone deacetylase (HDAC) biomarkers in multiple myeloma. Specifically, the biomarkers are drug specific, histone deacetylase (HDAC) or HDAC6 biomarker RNAs for multiple myeloma. The invention also relates to a kit for determining the treatment efficiency of a HDAC6 inhibitor, and a kit for identifying a histone deacetylase 6 (HDAC6) inhibitor. The invention further relates to a method for monitoring treatment efficiency of an HDAC inhibitor in a subject.

Abstract: The invention relates to combinations comprising an HDAC inhibitor and an immunomodulatory drug for the treatment of lymphoma in a subject in need thereof. Also provided herein are methods for treating lymphoma in a subject in need thereof comprising administering to the subject an effective amount of one of the above combinations.

Abstract: The invention relates to HDAC inhibitors, or combinations comprising an HDAC inhibitor and a BTK inhibitor for the treatment of non-hodgkin's lymphoma in a subject in need thereof. Also provided herein are methods for treating non-hodgkin's lymphoma in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an HDAC inhibitor, or a combination comprising an HDAC inhibitor and a BTK inhibitor.